REG - AstraZeneca PLC - Board Committee Changes

AstraZenecaAnnouncement

30/09/2022 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220930:nRSd2581Ba&default-theme=true

RNS Number : 2581B  AstraZeneca PLC  30 September 2022

30 September 2022 10:30 BST

 

 

Remuneration Committee Chair Appointment

 

AstraZeneca PLC today announced the appointment of Sheri McCoy, Non-Executive
Director, as Chair of the Remuneration Committee.  Sheri has served as a
member of the Remuneration Committee since July 2018.

 

Sheri will succeed Michel Demaré who will step down as Chair of the
Remuneration Committee following his recent appointment as Chair-designate of
the Board.  He will remain a member of the Committee.

 

Sheri will also become a member of the Nomination and Governance Committee.

 

These Remuneration Committee and Nomination and Governance Committee changes
are effective from 1 December 2022.  As previously announced, Michel Demaré
will become Chair of the Board at the end of the Company's Annual General
Meeting in April 2023.

 

 

Notes

 

Biography and photograph:

https://www.astrazeneca.com/our-company/leadership.html#board
(https://www.astrazeneca.com/our-company/leadership.html#board)

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPURWBUPPPUB